Will Walgreens Boots positive trend continue in Q1?
Walgreens Boots (NASDAQ:WBA) is scheduled to announce Q1 earnings results on Thursday, January 5th, before market open.
The consensus EPS Estimate is $1.14 (-32.1% Y/Y) and the consensus Revenue Estimate is $33.03B (-2.6% Y/Y).
Over the last 2 years, WBA has beaten EPS estimates 100% of the time and has beaten revenue estimates 88% of the time.

Over the last 3 months, EPS estimates have seen 2 upward revisions and 11 downward. Revenue estimates have seen 1 upward revision and 5 downward.

The drug retailer's stock rose on Oct. 13 after Q4 results beat analysts' estimates.
For the full fiscal year 2023, Walgreens expects adjusted EPS of $4.45 to $4.65. Consensus EPS Estimate of $4.51.
The company expects healthy core business growth of 8% to 10% in constant currency which is expected to be more than offset by adverse currency movements of ~2% and by a headwind of 15% to 17% from lower COVID-19 vaccination volumes.
The company raised U.S. Healthcare fiscal year 2025 sales target to $11B to $12B, from $9B to $10B previously. The segment is expected to achieve positive adjusted EBITDA by fiscal year 2024.
Walgreens also reconfirmed its expectation to achieve low-teens adjusted EPS growth in fiscal year 2025.
On Wednesday, Oklahoma's Attorney General Office said it has reached opioid settlements with Walgreens, CVS Health (CVS), Walmart (WMT), and AbbVie (ABBV) unit Allergan.
The companies have agreed to settle with Walgreens at $79.5M.
WBA is down ~30% in the last 12 months.